Background/Aims: TGF-β1 is beneficial during early liver disease but is tumor-progressive during late stages especially for hepatocellular carcinoma (HCC). Thus, exploring the underlying mechanisms may provide information about a potentially therapeutic role of TGF-β1 in HCC. Methods: Western blot and real-time quantitative PCR were used to quantify FGFR4 expression in HCC cell lines and a normal liver cell line. After constructing the best silencing FGFR4 expression vector, migration and invasiveness of TGF-β1 in HCC was studied in vitro and in vivo. Western blot was used to study the mechanism of TGF-β1 induction on FGFR4 expression with various inhibitors. Results: HepG2 cell lines had the most FGFR4 expression, and data show that silencing FGFR4 suppressed cell proliferation, invasion and migration in HCC induced by TGF-β1 in vitro and in vivo. Moreover, TGF-β1 induced FGFR4 expression through the ERK pathway. Conclusion: Promoting FGFR4 expression via the ERK pathway, TGF-β1 contributes to HCC invasion and metastasis.
TGF-β1 Promotes

Introduction
Liver cancer is a chief cause of cancer mortality worldwide [1] and hepatocellular carcinoma (HCC) represents the most common histological subtype, accounting for 70-85% of all cases of primary liver cancer globally. Mortality for HCC is high due to early metastasis [2] . Cell adhesion and progressively increased migration and invasiveness are key events in early tumor metastasis [3, 4] . Therefore, understanding cell adhesion, migration and invasion is useful for molecular diagnosis and prevention of HCC metastasis.
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TGF-β1 is a well known developmental factor involved in regulation of cell proliferation, differentiation, invasion, and inflammation. In mammals, the TGF-β family regulates many cellular functions, plays an important role in cell growth, differentiation, apoptosis, extracellular matrix (ECM) production, immunization, and even embryonic development [5] . TGF-β1 plays an important role in the pathogenesis of various liver diseases, such as fibrosis, cirrhosis, and HCC [6] .For example TGF-β regulates liver cancer development by inducing Treg cell polarization [7] . Plasma TGF-β1 in HCC patients was less than that for cirrhotic patients, if they had effective HCC therapy [8, 9] .
TGF-β1 has unique effects depending on tumor type and stage, and why this occurs is unclear. For example, TGF-β1 can inhibit cell proliferation in early stages of many malignancies, but for late-stage tumors, TGF-β1 promotes cancer progression, likely due to high autocrine or paracrine levels of TGF-β from the cancer itself or from the tumor microenvironment [10, 11] . Some cancer cells that lack TGF-β receptors may escape TGF-β-mediated inhibitory effects, leading to rapid cancer development [12] . Most tumors acquire a metastatic phenotype during progression, developing the capacity to invade surrounding tissues to migrate and grow at distant sites via an EMT-dependent process. Accumulating evidence shows that TGF-β1 has late-stage tumor effects, particularly for promoting EMT and cancer dissemination [13] .
Fibroblast growth factor receptor 4 (FGFR4) is a transmembrane tyrosine kinase receptor that regulates cell proliferation, apoptosis, metastasis and other processes after binding to ligands. Many studies confirmed high FGFR4 expression in breast, pancreatic, kidney cancers and other malignant tumors [14, 15] . FGFR4 can be degraded in the extracellular matrix via the FGF signaling pathway to regulate tumor invasion and metastasis [16] . Therefore, FGFR4 is oncogenic in HCC as well as tumor suppressive to drive differentiation and regulate other oncogene pathways, to protect cells from damage or regulate immune surveillance [17, 18] .
FGFR signaling thus has effects based on different cancer cell types and stages and FGFR and TGF-β signaling are similar, but their underlying crosstalk is not yet understood. Our previous work shows synergism with respect to the occurrence and progression of HCC according to clinicopathological features and patient prognosis [19] . In this study, we furthered studied the cooperation of FGFR4 and TGF-β1 in the invasion and metastasis of HCC; TGF-β1 promoted the invasion and metastasis of HCC by inducing FGFR4 expression in vitro and in vivo, and the ERK pathway was involved.
Materials and Methods
Cell culture
HepG2, BEL-7402, SK-hep-1, SMMC-7721, Hep3B and HCC-LM3 hepatoma cell lines and anormal HL-7702 liver cell line were purchased from Bogoo (Shanghai, China). Cells were grown in Dulbecco's modified Eagle's medium (DMEM) containing 10 % fetal bovine serum (FBS), 100U/ml penicillin G and 100 μg/ml streptomycin, and incubated at 37°C in a humidified incubator containing 5% CO 2 . Total RNA isolation and quantitative real-time PCR Total RNA was isolated using Trizol RNA extraction reagent(Life Technologies, Grand Island, NY) and reverse-transcribed into cDNA using SuperScript III First-Strand Synthesis System (Invitrogen). PCR reaction mixture was prepared using SYBR Green PCR Master Mix (Bio-Rad) using the primers as follows: FGFR4: 5'-CTGACCAAGCCAGCACTGTG -3' (F)，5'-TCAGAGGCGTTGTCTTTGAGC -3' (R); GAPDH： 5'-TGTTGCCATCAATGACCCCTT-3'(F), 5'-CTCCACGACGTACTCAGCG-3' (R). Thermal cycling conditions were 2 min at 95°C followed by 40 cycles of 95°C for 15 s and 60 °C for 15 s on a Real-Time PCR Detection System (Bio-Rad, USA), GAPDH was used as an internal control to normalize target gene transcripts.
Construction of FGFR4 miRNA-expressing vectors and transient transfection
FGFR4-miR-1-F 5'-TGCTGTACACTTCCGGGACTCCAGATGTTTTGGCCACTGACTGACATCTGGAGCCGGAAGTGTA -3' FGFR4-miR-1-R 5'-CCTGTACACTTCCGGCTCCAGATGTCAGTCAGTGGCCAAAACATCTGGAGTCCCGGAAGTGTAC -3' FGFR4-miR-2-F 5'-TGCTGTGTACACCCGGTCAAACAAGGGTTTTGGCCACTGACTGACCCTTGTTTCCGGGTGTACA -3' FGFR4-miR-2-R 5'-CCTGTGTACACCCGGAAACAAGGGTCAGTCAGTGGCCAAAACCCTTGTTTGACCGGGTGTACAC -3' FGFR4-miR-3-F 5'-TGCTGAAGACAGAATCGCTGGAGGAGGTTTTGGCCACTGACTGACCTCCTCCAGATTCTGTCTT -3' FGFR4-miR-3-R 5'-CCTGAAGACAGAATCTGGAGGAGGTCAGTCAGTGGCCAAAACCTCCTCCAGCGATTCTGTCTTC -3'
Western blot
Protein was measured using a BCA Assay (Beyotime Biotechnology), supernatant after centrifugation (4°C, 15min, and 15, 000rpm) was stored at -80°C. Then, 20 μg protein of per sample was resolved on 10% SDS-PAGE and electrophoretically transferred to PVDF membranes (AmershamHybondP, GE Healthcare, Buckinghamshire, UK). Membranes were blocked with 5% fat-free milk for 90 min and then incubated with primary antibodies (i.e., polyclonal rabbit antibodies against human FGFR4, smad2, smad4, and GAPDH) at 4°C overnight, followed by incubation with secondary antibodies for 1 hand visualized with an ECL Plus Western Blotting Detection System (GE Healthcare). Films were scanned or photographed and molecular weights and net light density of target bands were analyzed using a gel image processing system.
Cell viability assay CCK-8 (Dojindo Laboratories, Kumamoto, Japan) was used to assess cell viability. In brief, cells were seeded into 96-well plates (5.0×10 3 cells/well) and incubated with serum-free medium to a final volume of 100 ml. After being seeded for 48h, a plate was assayed by adding 10 ml CCK-8 solution to each well. Plates were incubated for 4 h in the dark at 37°C and absorbance at 450 nm was calculated. Each assay was performed three times.
Cell migration
HepG2 hepatoma cell lines were starved with serum-free DMEM medium (Hyclone) for 24 h before assays. Cells were digested for 5 min with 0.25% trypsin (Gibco, Shanghai, China) and resuspended in DMEM medium (Hyclone) containing 0.1%FBS. After counting, cells were diluted to 5×10 4 cells/ml, seeded in a 24-well Transwell plates and incubated for 24 h. Then, cells were fixed for 15 min using 1 ml/well 4% paraformaldehyde (JRDUN Biotech, Shanghai, China), stained by Giemsa (JRDUN) for 30 min, and washed three times with 1x PBS. Finally, Transwells without migrating cells were wiped carefully with a cotton swab, placed under a 200x lens, and cells were counted in random fields of 5-10.
Cell invasion
Into a 24-well Transwell plate, 50 μl diluted Matrigel was added to upper chambers and incubated at 37°C for 30 min. Cells in 1 ml of serum-free medium (1x10 5 cells/ml) were transferred to upper Matrigel chambers. Then, 1 ml of complete medium containing 10% FBS as chemoattractant was added to the lower chamber and cells were incubated at 37°C for 48 h. Cells that migrated were fixed and stained with 1 ml of 0.5% crystal violet for 30 min. Finally, invading cells in 5 randomly selected high-power fields were counted under amicroscope.
In vivo experiment
Treated HepG2 cells were digested with trypsin, centrifuged, and resuspended with complete medium. Then, 7x10
5 HepG2 cells were injected intraperitoneal into nude mice. After 1 month, tumor nodules were counted and collected and weighed and metastases were noted.
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Statistical analysis
All available data were recorded into the database and are presented as means ± SEM from at least three independent experiments. A Pearson Chi-squared test or Fisher's exact test was used to compare categorical variables and Mann-Whitney U test was performed for continuous variables (p<0.05 indicated statistical significance). Statistical analysis was carried out using SPSS16.0 (San Rafael, CA) software for Windows.
Results
Expression of FGFR4 in six HCC cell lines and one normal liver cell line
To examine the expression of FGFR4 in cell lines, we first examined the expression of FGFR4 mRNA in six HCC cell lines, Bel-7402, HepG2, SMMC-7721, Hep3B, SK-HEP-1, HCCLM3, and one normal liver cell line, HL-7702, using qRT-PCR. It showed that the expression of FGFR4 mRNA in the normal HL-7702 liver cell line was significantly lower than in the HCC lines (p<0.05, Fig. 1A ). HepG2 had the most FGFR4 mRNA among the HCC cell lines, followed by the Bel-7402 and SMMC-7721 lines (Fig. 1A) . FGFR4 protein expression data showed that HL-7702 cells had less FGFR4 protein than the HCC lines, and HepG2 had the highest FGFR4 protein, followed by HCCLM3 and Bel-7402 (Fig. 1B) . Quantitative analysis showed that FGFR4 expression was increased approximately 5-fold in HepG2, 4.2-fold in HCCLM3, and 3.9-fold in Bel-7402cells. Thus, the HepG2 cell line was chosen for the remaining experiments.
Construction of FGFR4 miRNA-expressing vectors and silencing effect
To silence FGFR4 expression, we used the pcDNA TM 6.2-GW/EmGFP-miR eukaryotic expression vector. Three recombinant plasmids for miRNA targeting of FGFR4, pcDNA TM 6.2-miR4-1, 2, and 3, were constructed ( Fig. 2A) . After transfection and screening, GFP expression was measured in all transfected HepG2 cells (Fig. 2B) . Quantitative analysis of the Western blot data showed that pcDNA6.2-miR4-1 was the best silencer of FGFR4 expression compared with pcDNA6.2-miR4-2, 3, pcDNA6.2-miR4-control and NC (p<0.01; Fig. 2C, 2D) . Therefore, pcDNA6.2-miR4-1 was selected for the following studies.
TGF-β1 inhibits HepG2 cell proliferation via FGFR4
TGF-β1 (2, 5, and 10 ng/ml) dose-dependently blocked HepG2 cell proliferation compared with low concentrations of TGF-β1 (0.5 and 1ng/ml; p<0.05) (Fig. 3A) .
To explore whether FGFR4 was related to TGF-β1, pcDNA TM 6.2-miR4-1 was used to knock down FGFR4 expression in HepG2 cells. This did not change outcomes between TGF-β1 and TGF-β1-free groups for pcDNA6.2-miR4-1, but 10 ng/ml TGF-β1 treatment of the pcDNA6.2-miR4-1 group resulted in more proliferation compared with pcDNA6.2-miR4-control and NC groups (*p<0.05, **p<0.05) (Fig. 3B) .
FGFR4 knockdown inhibited migration and invasion mediated by TGF-β1 in HepG2 cells
TGF-β1 is known to promote the migration and invasion of HCC cancer cells [20] . To investigate whether TGF-β1 facilitates HCC migration and invasion by regulating FGFR4 expression, we examined the impact of FGFR4 knockdown on migration (Fig. 3C ) and invasion ( Fig. 3D ) mediated by TGF-β1 in HepG2 cells using Transwell migration and invasion assays. With 10 ng/ml TGF-β1, NC and pcDNA6.2-miR4-control groups had greater migration and invasion compared with the pcDNA6.2-miR4-1 group. There were differences in TGF-β1 and TGF-β1-free pcDNA6.2-miR4-control and NC groups but not for the pcDNA6.2-miR4-1 group. Thus, FGFR4 is essential for TGF-β1-mediated HCC metastasis.
Knock down of FGFR4 represses TGF-β1 mediated HCC invasion in vivo
Next, we examined the effects of FGFR4 on HCC metastasis by establishing an HCC metastasis model in nude mice using a stable FGFR4-knockdown HepG2 cell line with or without TGF-β1. All mice were sacrificed after 1 month, and the macroscopic examination results shown in Fig. 4A indicates that nodules from mice were greater in TGF-β1-treated pcDNA6.2-miR4-controls compared to the pcDNA6.2-miR4-1 group. Also, there was a difference between TGF-β1 and TGF-β1-free pcDNA6.2-miR4-control and NC groups but not for the pcDNA6.2-miR4-1 group (*p<0.05, **p<0.05) (Fig. 4B) .
Histology confirmed that with TGF-β1, liver metastasis developed in the pcDNA6.2-miR4-1, pcDNA6.2-miR4-control and NC groups, and this occurred less than in TGF-β1-free groups (Fig. 4C, 4D ). There was a significant difference between TGF-β1 and TGF-β1-free in the pcDNA6.2-miR4-control and NC groups but not for the pcDNA6.2-miR4-1 group. Thus, TGF-β1 mediated HCC invasion and metastasis via FGFR4 in vivo.
TGF-β1 mediates FGFR4 expression via the ERK pathway
It is believed that TGF-β signaling occurs via a canonical and a noncanonical pathway. For the canonical pathway, it is known that Smad2 and Smad4 play important roles. In order 
to explore the molecular mechanism through which TGF-β1 mediates FGFR4 expression, we used specific si-Smad2 and si-Smad4 to interfere with the canonical pathway to explore the impact on FGFR4 expression. After transfection with si-Smad2 or si-Smad4, Western Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry blotting analysis showed that there was no difference between TGF-β1 and TGF-β1-free for FGFR4 expression (Fig. 5A , 5B). Thus, the canonical pathway is not used for TGF-β1-mediated FGFR4 expression. The TGF-β noncanonical activation pathway is associated with the phosphorylation of several intracellular proteins, such as ERK, N-terminal kinase (JNK), and p38. By using specific data from experiments with the ERK inhibitor PD98059, the JNK inhibitor SP600125, and the p38 inhibitor SB203580, with/without 10 ng/ml TGF-β1, we found that irrespective of TGF-β1, PD98059 decreased FGFR4 expression significantly. Also, TGF-β1 promoted FGFR4 expression compared with the TGF-β1-free group (Fig. 5C, 5D ). With SP600125 and SB203580, TGF-β1 promoted FGFR4 expression significantly compared to the TGF-β1-free group. However, the 10 ng/ml TGF-β1 group was not different compared to the NC group (Fig. 5C-F) . Therefore, our results showed that TGF-β1 mediates FGFR4 expression via the ERK pathway.
Discussion
Here, we demonstrated that FGFR4 reversed the inhibitory effects of TGF-β1 on HepG2 cell proliferation, migration, and invasion, and TGF-β1 activity was restrained by silencing FGFR4 expression. Moreover, tumor nodules induced by HepG2 cells were smaller and metastasized less without FGFR4 expression. Also, the canonical pathway by which TGF-β1 regulates FGFR4 expression was not used, but the ERK pathway was used instead. Thus, FGFR4 is involved in TGF-β1-induced migration and invasion of HCC cells.
In early tumor cells, TGF-β is considered to be a tumor suppressor because it is cytostatic and apoptotic. In our studies, we observed a suppressive effect of TGF-β1 on HepG2 cells (Fig. 3A) . However TGF-β switches to tumor promotion later, and intrinsic and extrinsic factors may contribute to this. Intrinsic factors include transformation of tumor FGF19 is a unique ligand that binds to FGFR4, and overexpression of both are associated with HCC [21] . FGFR4 contributes to angiogenesis, tissue differentiation and repair. FGFR4 is highly expressed in embryonic tissues and overexpressed in many tumor tissues, such as prostate, breast, and pancreatic cancers, and HCC [22] [23] [24] [25] . Data show that FGFR4 has an oncogenic role in HCC and chemotherapeutic resistance, and tumor invasion is related to high expression of FGFR4 [26] [27] . However, high expression of FGFR4 contributes to apoptosis and better prognoses [25] . The role of FGFR4 is likely influenced by cellular context and crosstalk with other signaling pathways.
There are few studies that have described a connection between TGF-β and FGFR4. Our previous work showed that FGFR4 expression was associated with the prognosis of HCC and was correlated with TGF-β expression [19] . Using immunohistochemistry (IHC) and clinical postoperative follow-up data, we assessed crosstalk between FGFR4 and TGF-β1 in HCC. We also report that TGF-β1 had invasive and metastatic effects by inducing FGFR4 in vitro and in vivo, and the mechanism of TGF-β1 may induce FGFR4 expression through the ERK pathway.
The TGF-β signaling pathway includes canonical and noncanonical non-Smad signaling. Non-Smad signaling can activate various pathways such as JNK and PI3K, P38, and ERK MAP kinase. For the ERK pathway, TβRI is activated by binding with the TGF-β1 ligand, and then TβRI phosphorylates SRC homology domain 2-containing protein (SHC) on serine and tyrosine residues, which recruits GRB2 and SOS proteins. This activates ERK MAPK signaling [28] . We used various inhibitors against ERK, JNK and p38 MAPKs, and TGF-β1 induced FGFR4 expression via the ERK pathway in HCC. Previous studies reported that changes in FGFR4 expression may activate ERK pathways in lung cancer [29] , prostate cancer [30] , and studies show that low expression of FGFR4 may cause reduced ERK pathway signaling in breast cancer [31] . Thus, crosstalk among TGF-β1, FGFR4 and the ERK pathway requires more study.
TGF-β targeting agents have potent antitumor effects, but synergistic activity may improve their effects if any can be identified. For example, combination treatment with the TβRI inhibitor LY364947 and erlotinib suppressed the motility of NSLCL cells [32] , and we report synergy between TGF-β1 and FGFR4 for treatment of HCC. Thus, drugs that target two molecules may be an improved strategy for treating HCC.
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